Form 4 for AQST Aquestive Therapeutics, Inc.
Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-08 · accession 0001214659-24-004389 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | 2024-03-08 | AQST | Schobel Alexander Mark | Chief Innovation, Tech Off | S - Sale | $5.19 | -25.0K | 1.04M | -2% | -$129.8K | |
| 2024-03-12 | 2024-03-09 | AQST | Schobel Alexander Mark | Chief Innovation, Tech Off | F - Tax | $4.88 | -5,895 | 1.03M | -0.6% | -$28.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | S | D | 25,000 | $5.19 | 1,040,371 | D | — | — | (F2) Represents the weighted average sales price per share. The shares sold at prices ranging from $5.00 to $5.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 2 | Common | Common Stock | 2024-03-09 | F | D | 5,895 | $4.88 | 1,034,476 | D | — | — |